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core-set were also obtained both at baseline and 4 week apart. These included
tender joint count (out of 28), swollen joint count (out of 28), physician’s and pa-
tient’s global assessment of disease activity, pain score and Westergren erythro-
cyte sedimentation rate (ESR). Disease activity was measured using the DAS28
score, which was obtained at baseline and at the end of the study for each patient.
RESULTS: The median age of the 60 study patients was 48 yr 9.5SD and the
median duration of symptoms was 17months5.5SD. Thirty of these received the
English version of the HAQ and the other 30 received the Hindi version. Baseline
HAQ values for English and Hindi groups were 1.840.48 and 1.910.49, respec-
tively. After treatment, the HAQ values changed to 0.710.42 and 0.620.51, re-
spectively, demonstrating a very good sensitivity to change (Student’s unpaired
t-test: p0.05). Construct validity was assessed using Pearson’s correlation coeffi-
cient between the corresponding values of HAQ and DAS28, both at baseline
(r0.47, p0.05) and after intervention (r0.60, p0.01). CONCLUSIONS: These re-
sults support the validity, and reliability of the IND-HAQas ameasure that captures
the impact of RA on patients’ health-related quality of life.
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OBJECTIVES: The ENSEMBLE MDS is a battery of phenotypic generic patient-re-
ported instruments designed for use in clinical studies or comparative effective-
ness research. The component instruments assess baseline patient characteristics
that are believed to be either predictors (health status, illness burden, depression,
anxiety, and perceived stress) or effect-modifying factors (perceived social status,
objective social status, perceived social support, income) of clinical outcomes
and/or treatment response. We sought to evaluate the equivalence of the MDS
across two different modes of administration – paper and web. METHODS: This
study was a data collection effort that used a randomized cross-over design in the
United States (English) and Singapore (Simplified Chinese). Participants were out-
patients with a clinical diagnosis of one of five targeted health conditions: depres-
sion, type 2 diabetes, psoriasis, rheumatoid arthritis and chronic kidney disease.
Those enrolled were randomized to initially complete the MDS on paper or web
format, and returned 24 hours later to complete the alternate format. Equivalence
was evaluated by the intraclass correlation coefficient (ICC) with equivalency de-
fined at or above the minimal acceptable level of 0.70. These analyses were per-
formed individually for each of the nine MDS component measures. RESULTS: A
total of 314 participants (258 in US, 56 in Singapore) were analyzed. In the US,mean
age was 4913 years, 61% were female; in Singapore mean age was 5712, 59%
female. The ICCs between paper and web administration of the different compo-
nents of the ENSEMBLE MDS ranged between 0.74 and 0.98 in the US, and between
0.75 and 0.97 in Singapore. CONCLUSIONS: Equivalence between paper and web-
based administration of the ENSEMBLEMDSwas demonstrated statistically for the
US-English Version and the Chinese version for Singapore, indicating stability of
subject comprehension and response patterns across twomodes of administration
in two different languages and cultures.
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OBJECTIVES: The growth in patient empowerment and increase in on-line patient
pools has given rise to new direct-to-patient research methods (i.e., direct recruit-
ment of patients, without physician sites). One key concern, however, is the ab-
sence of physician-reported data to validate diagnosis and provide other study
data. The objective of this study was to employ a direct-to-patient approach to
collect patient-reported outcomes (PRO) and medical record (MR) information.
METHODS: In July 2011, a random sample of US MediGuard.org members age 18 to
80 were invited to participate via email based on a gout treatment or diagnosis in
their profile. Interestedmembers clicked on an email link to access study informa-
tion and screen based on self-reported diagnosis andwillingness to releasemedical
records. The first 50 consenting participants continued on to complete an online
survey and electronic and paper medical release forms. Completed forms were
provided to Outcomes Health Information Solutions to contact physicians and
obtain participant charts. RESULTS: A total of 120 members clicked on 1250 emails
sent (9.6%). 5 members (4%) explicitly declined to participate due to the medical
record requirement, although this could be as high as 38% if all individuals closing
the browser are included. Of the 50 participants completing the on-line survey and
electronic release, 42 (84%) returned the paper form.With these forms,we obtained
38 of 50 charts (76%): 28 of 38 (74%) with electronic and 10 of 38 (26%) with paper; 35
charts had a gout diagnosis and an additional 2 had a goutmedication; only 1 chart
was missing any mention of gout. CONCLUSIONS: Patients can be recruited di-
rectly for observational study designs that include PRO and MR data with over 75%
data completeness. Although concern exists regarding validity of self-reported di-
agnosis, in this PROMR pilot, nearly all (37 of 38) charts confirmed patient-re-
ported data.
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OBJECTIVES:Omalizumab is amonoclonal antibody, indicated for the treatment of
severe allergic asthma. In Europe, there have been concerns about the cardiovas-
cular safety of omalizumab. The objective of this study is to analyze the association
between omalizumab and arterial thrombotic events (ATE) in spontaneous adverse
drug reaction reporting database in the United States. METHODS: Reports of ATE
submitted to the US Food and Drug Administration’s Adverse Event Reporting
System (AERS) between 2004 and 2011were retrieved and analyzed by the reporting
odds ratio (ROR) data mining algorithm. The ROR of ATE for omalizumab was
compared to specific asthma medications and all drugs in the AERS. Values of 1
are considered significant safety signals. Medical Dictionary for Regulatory Activi-
ties (MedDRA) Preferred Terms were used to retrieve ATE (e.g. stroke, myocardial
infarction). RESULTS: A total of 293,783 reports of ATE were retrieved (about 2% of
all ADR reports), corresponding to 2,274 asthma drug-event pairs (omalizumab,
222; inhaled corticosteroids (ICS), 131; long-acting beta-agonists (LABA), 102; sin-
gle-device combination ICS/LABA, 506; inhaled short-acting beta-agonists (SABA),
475; oral SABA, 6; inhaled antimuscarnics (AMC), 477; single-device combination
AMC/SABA, 127; xanthines, 50; leukotrienemodifiers, 174; andmast cell stabilizers,
4). ROR and 95%CI values for omalizumab compared to other asthma drugs and all
drugs in AERS were 2.75 (2.39-316) and 1.09 (0.95-1.24), respectively. Omalizumab
ranked the second after ICS in the risk of ATE; followed by AMC, AMC/SABA, and
ICS/LABA. CONCLUSIONS: Omalizumab is associated with higher than expected
reporting of arterial thrombotic events in asthmatic patients. This hypothesis
needs further testing in robust epidemiologic studies.
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OBJECTIVES: To evaluate the incidence of various side effects in newly diagnosed
tuberculosis patients of Khyber Pakhtoon Khuwa. METHODS: Quantitative study
was conducted to evaluate the incidence of side effects in tuberculosis patients.
Data was collected fromMedicine, Infectious diseases, and chest and gastroenter-
ology unit of the Ayub Teaching Hospital and T.B center at DHQ Hospital of KPK. A
total of 125 random newly diagnosed patients were included in the studies which
were given 1st line ATT which include Rifampicin, Pyrazinamide, Isoniazid and
Ethambutol. This 4 drug regimen was given to initiate the therapy. A formal con-
sent was taken from the patient or the attendant. The patients were examined for
signs of previous liver or kidney disease by physical examination. Liver function
tests and urine RE, as well as blood CP and hematological investigations. RESULTS:
Patients were given 4 drug regime i.e., isoniazid (INH),rifampicin, pyrazinamide
and ethambutol. A total of 31.97% patients experienced nausea; 25.4% patients
experienced anorexia; 13% patients experienced vomiting; and 11.4% patients ex-
perienced diarrhea. Hypersensitivity reaction were also noticed, 12.3 % people suf-
fered from fever. Skin rashes were experienced by 16 (13.11%) patients. Hepatotox-
icity was seen in 9.01% patients; (0.82%) patients suffered from thrombocytopenia
whowas a female; 1.64% patients experienced renal failure; 1(50%) was amale and
1(50%)was a female; and 99.18% patients experienced urinary discolouration out of
which 81 (66.94%) were males and 34 (28.1%) were females. Two patients (1.64%)
experienced acne, bothweremales.CONCLUSIONS:Various adverse effects of Anti
Tuberclosis Therapy have been observed in the patients ranging from the minor
symptoms like skin rashes and GI disturbances to serious effects like renal failure,
hepatotoxicity, thrombocytopenia, hyperuricemia which may be fatal. There is a
need of optimal patient care during the period of therapy. Many of these side
effects can be avoided by altering the regimen and proper counseling.
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OBJECTIVES: Inhaled anticholinergics are important pharmacologic interventions
in the management of Chronic Obstructive Pulmonary Disease (COPD) with tiotro-
pium bromide being themost prescribed COPDmedication. Concerns regarding its
association with cardiovascular adverse events have been raised. The objective of
this study was to assess the risk of all-cause mortality associated with inhaled
anticholinergics among COPD patients using systematic-review with meta-analy-
sis techniques.METHODS: A systematic literature search was conducted using six
electronic databases (PubMed, Scopus, Web-of-Science, Web-of Knowledge, Co-
chrane Central Register of Controlled Trials and Proquest) and cross-referencing.
Studies meeting the following eligibility criteria were selected: 1) randomized con-
trolled trials (RCTs) withmortality data; 2) adults aged greater35 yearswith COPD
of any severity; 3) inhaled anticholinergics (ipratropium bromide or tiotropium
bromide) with a minimum follow-up of 4 weeks; and 4) placebo or active control
group. Studies including asthma patients were excluded. Data extraction was per-
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